ALLO
ALLO
US0197701065
Allogene Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- 22.000
--
Cost of Revenue -- --
--
Gross Profit -- --
--
206.933.000 257.504.000
19.6%
Operating Income -206.933.000 -257.482.000
19.6%
Pretax Income -190.886.000 -257.147.000
25.8%
Net Income Common Stockholders -190.886.000 -257.590.000
25.9%
-- --
--
-- --
--
ende